One tool to predict adverse drug reactions—Meet your new PGx powerhouse

Every year, adverse drug events affect over 134 million patients and claim 2.4 million lives globally. But what if there was a faster, smarter way to predict and prevent these outcomes—before they happen?

Join us to discover QIAGEN Pharmacogenomic Insights (PGXI), a revolutionary tool built to help labs and pharmaceutical companies turn complex pharmacogenomics (PGx) data into clear, actionable insights—fast. PGXI delivers instant access to expertly curated, up-to-date information from trusted sources like the FDA, CPIC, DPWG, PharmVar, and PubMed, all in one seamless platform.

Proven through the annotation of more than 1.6 million PGx findings across 250+ labs, PGXI integrates effortlessly into any workflow, whether you're working with NGS, arrays, or hybrid models. In just minutes, you can confidently identify drug-gene associations, uncover conditions linked to critical variants, and access peer-reviewed evidence—all customized to your specific genes of interest.

In this webinar, you’ll learn how PGXI can:

Help you efficiently and consistently pinpoint medications linked to adverse effects.
Save time and cut costs with centralized, expert-curated content.
Future-proof your lab by scaling your PGx capabilities with confidence.

Plus, if eligible, webinar attendees can try PGXI for free with an exclusive trial offer from QIAGEN. There’s an easier and faster way to translate PGx data into insights. Don’t miss this opportunity to elevate and transform your PGx program.

About the speaker

Elias Hage, PhD, Director, Clinical Global Product Management

QIAGEN Digital Insights

Elias Hage, PhD, is the Director of Clinical Global Product Management at QIAGEN Digital Insights (QDI). In this role, he oversees the development, management, and optimization of QDI software, databases and services for genomic analysis and interpretation of hereditary disease and oncology cases. Prior to joining QDI, Dr. Hage served as a Global Product Manager at Agilent Technologies, where he managed the Genomics division flagship SaaS application (Alissa Interpret) and supported its usage globally in both research and IVD settings. Dr. Hage obtained his PhD in virology and genomics from Hannover Medical School in Germany.

Ann Bailey, PhD, Lead Clinical Genetics QA Associate Staff Scientist

QIAGEN Digital Insights

Ann Bailey, PhD is a Lead Clinical Genetics QA Associate Staff Scientist at QIAGEN, where she leverages nearly 13 years of experience to ensure the highest quality standards in clinical genetics and cancer biology. In her current role, Ann leads efforts to support precision medicine initiatives, contributing to the development and validation of decision support solutions for molecular diagnostic assays.Previously, Ann served as a Precision Oncology Scientist at MD Anderson Cancer Center. At MD Anderson, she was an integral member of the Institute for Personalized Cancer Therapy, investigating the molecular profiling of tumors to guide treatment strategies. Ann's work in precision oncology has been widely published, and she has contributed to advancing biomarker-driven cancer therapies.In addition, Ann has a rich research background, having completed her postdoctoral fellowship in translational cancer research at MD Anderson Cancer Center. Her academic journey also includes work as a graduate assistant at the University of Kansas Medical Center, with graduate training in pharmacology, toxicology, pharmacogenomics, epigenetics and cancer biology.